DexCom, Inc. (NASDAQ:DXCM) Shares Acquired by King Luther Capital Management Corp

King Luther Capital Management Corp raised its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 35.9% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 213,245 shares of the medical device company’s stock after purchasing an additional 56,365 shares during the period. King Luther Capital Management Corp owned 0.05% of DexCom worth $14,296,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of the stock. Jennison Associates LLC lifted its stake in DexCom by 1,683.2% in the 3rd quarter. Jennison Associates LLC now owns 6,932,899 shares of the medical device company’s stock valued at $464,782,000 after buying an additional 6,544,102 shares in the last quarter. Legal & General Group Plc lifted its position in shares of DexCom by 1.7% in the second quarter. Legal & General Group Plc now owns 2,993,049 shares of the medical device company’s stock valued at $339,352,000 after acquiring an additional 49,076 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its stake in shares of DexCom by 16.9% in the second quarter. Massachusetts Financial Services Co. MA now owns 2,439,033 shares of the medical device company’s stock worth $276,538,000 after acquiring an additional 353,019 shares during the last quarter. Vaughan Nelson Investment Management L.P. raised its stake in DexCom by 14.4% in the 2nd quarter. Vaughan Nelson Investment Management L.P. now owns 1,617,001 shares of the medical device company’s stock valued at $183,336,000 after purchasing an additional 203,043 shares during the last quarter. Finally, Rathbones Group PLC lifted its holdings in DexCom by 5.8% in the 2nd quarter. Rathbones Group PLC now owns 1,401,802 shares of the medical device company’s stock valued at $158,936,000 after purchasing an additional 76,727 shares in the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

Insider Transactions at DexCom

In other news, EVP Sadie Stern sold 426 shares of DexCom stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $29,457.90. Following the sale, the executive vice president now owns 75,451 shares in the company, valued at approximately $5,217,436.65. The trade was a 0.56 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, COO Jacob Steven Leach sold 746 shares of the company’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $51,585.90. Following the completion of the sale, the chief operating officer now directly owns 264,915 shares of the company’s stock, valued at approximately $18,318,872.25. This trade represents a 0.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.30% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently issued reports on DXCM. BTIG Research dropped their price objective on shares of DexCom from $156.00 to $120.00 and set a “buy” rating for the company in a research note on Friday, July 26th. Piper Sandler reaffirmed an “overweight” rating and issued a $90.00 target price on shares of DexCom in a research report on Monday, August 26th. Wells Fargo & Company lifted their price objective on DexCom from $80.00 to $90.00 and gave the company an “overweight” rating in a research note on Friday, October 25th. Baird R W downgraded shares of DexCom from a “strong-buy” rating to a “hold” rating in a research note on Friday, July 26th. Finally, Raymond James decreased their price target on shares of DexCom from $115.00 to $99.00 and set a “strong-buy” rating for the company in a research report on Friday, October 25th. Seven investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $104.59.

DexCom Price Performance

DXCM stock opened at $74.48 on Friday. The business has a 50 day moving average price of $70.43 and a 200 day moving average price of $90.34. The company has a quick ratio of 2.12, a current ratio of 2.46 and a debt-to-equity ratio of 1.23. The stock has a market cap of $29.09 billion, a price-to-earnings ratio of 44.60, a PEG ratio of 2.30 and a beta of 1.17. DexCom, Inc. has a fifty-two week low of $62.34 and a fifty-two week high of $142.00.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.